Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Pluri Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
PLUR
Nasdaq
8731
https://pluri-biotech.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Pluri Inc
Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method
- Apr 8th, 2024 11:00 am
Pluri’s Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences
- Mar 28th, 2024 11:15 am
Pluri Inc. Announces 1-for-8 Reverse Share Split
- Mar 27th, 2024 11:00 am
Pluri’s Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report
- Mar 21st, 2024 11:00 am
Engage with Pluri's Talent: Exciting Conference Appearances Ahead
- Mar 19th, 2024 8:00 am
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
- Mar 14th, 2024 11:00 am
Pluri™ Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
- Mar 11th, 2024 11:00 am
Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board
- Mar 6th, 2024 12:00 pm
Pluri’s Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals
- Feb 28th, 2024 12:00 pm
Pluri Second Quarter 2024 Earnings: US$0.12 loss per share (vs US$0.24 loss in 2Q 2023)
- Feb 14th, 2024 11:53 am
Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis
- Jan 23rd, 2024 7:00 am
Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization
- Jan 8th, 2024 12:00 pm
Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction
- Dec 21st, 2023 12:00 pm
Pluri Full Year 2023 Earnings: US$0.77 loss per share (vs US$1.28 loss in FY 2022)
- Sep 14th, 2023 10:07 am
Pluri’s PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation
- Aug 16th, 2023 11:00 am
Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors
- Jul 13th, 2023 6:00 am
Deutsche Bank Predicts up to 160% Rally for These 3 Stocks — Here’s Why They Have Solid Upside
- Jul 12th, 2023 3:17 pm
U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluri’s PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome
- Jul 11th, 2023 6:00 am
Scroll